Universität Stuttgart

Coastal seas form a complex transition zone between the two largest CO2 sinks in the global carbon cycle: land and ocean. Ocean researchers have now succeeded for the first time in investigating the role of the coastal ocean in a seamless model representation. Coastal seas form a complex transition zone between the two largest CO2 sinks in the global carbon cycle: land and ocean. Ocean researchers have now succeeded for the first time in investigating the role of the coastal ocean in a seamless model representation. The team led by Dr. Moritz Mathis from the Cluster of Excellence for Climate Research CLICCS at Universität Hamburg and the Helmholtz-Zentrum Hereon was able to show: The intensity of CO2 uptake is higher in coastal seas than in the open ocean. This is evidenced by a study published in the journal Nature Climate Change. To counteract ongoing climate change, it is important to understand how CO2 emissions are distributed. And which exchange processes between the atmosphere, ocean and land regulate the distribution. Methodological developments in recent years have allowed for a more flexible inclusion of physical and biogeochemical processes in climate models and for capturing individual regions with higher resolution. Researchers from the Cluster of Excellence "Climate, Climatic Change, and Society" (CLICCS) have taken advantage of this. In collaboration between Helmholtz-Zentrum Hereon, Universität Hamburg, Max Planck Institute for Meteorology and University of Bern, they have developed a new type of ocean model that can efficiently simulate the transport, storage and turnover of carbon in the global coastal ocean for the first time: ICON-Coast. More realistic representation In computational climate science, land and ocean, the Earth's two major carbon reservoirs, have so far been considered separately. The transport of carbon into the coastal seas, for example via river inputs, coastal erosion and tidal flats, has been ignored. Coast-specific processes could only be considered in a limited and spatially coarse manner because climate models were developed for global scales. Due to the more realistic representation and higher resolution in the transition zone between land and ocean used in ICON-Coast, the model offers new possibilities to explore the effects of climate change on coastal areas and marine ecosystems, such as risks from heat waves, storms, or global sea level rise. The coastal ocean is small but significant It is known from observations that the increase in atmospheric CO2 concentration enhances the uptake of CO2 into the ocean, thereby significantly mitigating climate change. Simulations with ICON-Coast now shed light on the causes and enable understanding of the function of coastal and marginal seas in the Earth's climate dynamics: "Our analyses show that intense plankton growth is the key to enhanced CO2 uptake in the coastal ocean and that this uptake is higher than in the open ocean. This is due to climate-induced changes in the circulation and increasing nutrient inputs from rivers," says Dr Moritz Mathis, who led the study. The researchers also expect that the intensity difference between coastal seas and the open ocean will continue to strengthen further with ongoing CO2 emissions. All the more important: "Coastal management strategies that disturb biological production could weaken the ocean's CO2 uptake and make climate protection more difficult," emphasizes Mathis. "With the new model, we can also test approaches to CO2 avoidance such as offshore wind energy for their effectiveness and undesirable side effects."

- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development at USC Norris. He is also Professor of Medicine and Preventive Medicine and the J Terrence Lanni Chair for Cancer Research in the Division of Medical Oncology with Keck School of Medicine of USC. “Microsatellite stable (MSS) colorectal cancer (CRC) remains one of the cold tumors where effective immunotherapy still remains elusive and I believe anti-CTLA-4 therapy should be part of the solution,” said Dr. Lenz. “By enabling CTLA-mediated intratumoral Treg depletion, the masked, anti-CTLA-4 ADG126 (muzastotug) in combination with pembrolizumab has shown compelling results in phase 2 dose expansion in MSS CRC. The safety profile of ADG126 allows higher, more frequent and repeat doses of anti-CTLA-4 in combination with anti-PD-1 therapies, and has the potential to significantly improve longer-term survival benefit for patients with serious unmet medical needs.” An active researcher, Dr. Lenz’s National Cancer Institute-funded laboratory is developing novel agents in his preclinical models in GI cancer. As a transformational clinical investigator and translational scientist, Dr. Lenz was the first to lead the first prospective randomized Phase II trials using gene expression from FFPE specimens. He also discovered that primary tumor location of colorectal cancer (CRC) is an independent predictive and prognostic marker, now in the NCCN guidelines. Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials. Dr. Lenz earned his M.D. degree at the Johannes-Gutenberg Universität in Mainz, Germany. In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany. He obtained special fellowship training at Universität Wien (Austria), George Washington University and Harvard Medical School. He has published over 570 peer reviewed manuscripts with an h-index of 113. “We share Dr. Lenz’ vision that anti-CTLA-4 therapy is an essential solution to bring immunotherapy to cancer patients with cold tumors like MSS CRC,” said Peter Luo, Ph.D., Chairman, CEO and President of R&D at Adagene. “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.” For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/ About AdageneAdagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues. Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (TREGs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers. For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and Twitter. SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union. Safe Harbor Statement This press release contains forward-looking statements, including statements regarding the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated clinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Investor & Media Contact Ami Knoefler650-739-9952ir@adagene.com

TORINO, Italy--(BUSINESS WIRE)-- Resalis Therapeutics today announced the appointment of Almut Nitsche, PhD, as its Chief Medical & Development Officer (CMDO). Dr. Nitsche brings with her over 25 years of experience in the pharmaceutical industry, particularly in drug development and project management, at companies including Sanofi and Aventis. In her role at Resalis, she will spearhead the clinical development of RES-010, a non-coding RNA drug candidate designed to address obesity. “Almut’s extensive track record in new product development and healthcare solutions, coupled with her deep expertise in metabolic disease and diabetes, positions her as an important addition to our team to guide our clinical development strategy. She joins us at the right moment as we near completion of our preclinical development for RES-010 and move toward our first-in-human trial,” said Alessandro Toniolo, CEO of Resalis Therapeutics. “Resalis' RES-010 candidate, developed based on cutting-edge metabolic disease insights, offers a unique opportunity to develop an orthogonal approach to currently marketed obesity treatments. I look forward to joining the Resalis team as we advance into the Phase 1 trial and seek to establish initial clinical proof of concept for RES-010,” added Almut Nitsche, CMDO of Resalis Therapeutics. Dr. Almut Nitsche is a seasoned expert in pharmaceutical research and development. Prior to joining Resalis, she served as a consultant to Proxidrugs and worked for over 17 years at Sanofi, holding key positions such as Project Director for Early Development and Project Director for R&D in the Diabetes Division. Before this, she held positions at Aventis (acquired by Sanofi) and Hoechst Marion Roussel Genomic Center. As part of her commitment to therapeutic innovation in the metabolic disease space, Dr. Nitsche has also served as a Management Board Member at INNODIA, an international non-profit organization accelerating the development of new cures for type 1 diabetes. She holds a PhD in Biochemistry and Molecular Biology from the University of Stuttgart, Germany. About Resalis Therapeutics Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders. For more information visit our website . View source version on businesswire.com: Contacts Contact Resalis Alessandro Toniolo, CEO +393386092544 alessandro.toniolo@resalistherapeutics.com Media Relations Trophic Communications Gretchen Schweitzer or Dr. Charlotte Spitz Trophic Communications +49 171 351 2733 resalis@trophic.eu Source: Resalis Therapeutics View this news release online at: